Dr Shaji Kumar highlights bispecifics under development and how BCMA-targeting therapies impact patient selection for the treatment of R/R multiple myeloma.This is a modal window. This video is either unavailable or not supported in this browserError Code: MEDIA_ERR_SRC_NOT_SUPPORTED...
EP: 3.Bispecifics Under Development for The Treatment of R/R Multiple Myeloma EP: 4.Monitoring and Management of Adverse Events Associated with Bispecifics in MM Now Viewing EP: 5.Advice to Community Oncologists Treating with Bispecifics and Unmet Needs in MM ...
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience Teclistamab is a B cell maturation antigen (BCMA)-directed bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM) on the basis of the......
BCMA-Targeting Agents in the Treatment of Multiple Myeloma: Right Patient, Right Time : Episode 9 Video March 28, 2022 BCMA-Targeting Bispecifics for the Treatment of RRMM Author(s): Sagar Lonial, MD,Karen L. Klugo, MD+1 MoreAn overview of novel bispecific therapies under development in...
Janssen Korea said Tuesday it has received approval from the Ministry of Food and Drug Safety for the multiple myeloma treatment Talvey Inj. (talquetamab).The indication for domestic approval is monotherapy for adult patients with relapsed or refractory
A Novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretionBackground B-cell maturation antigen (BCMA) is a potential therapeutic target in treatment of patients with MM. BCMA is widely expressed at the surface of myeloma cells and ...
Oncology and assistant professor of pharmacy, Mayo Clinic College of Medicine, on his presentation at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference 2024 in Tampa, Florida titled “Key Considerations for Operationalizing Bispeci...
(3D) structures derived from primary healthy or tumour tissue samples—are coming of age as powerful preclinical models owing to their ability to preserve morphological, genetic and functional features of the parental tissue14,15. The value of organoids in oncology research and personalized medicine ...
(talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, ...
Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.Inventors: Engelberts, Patrick (Utrecht, NL) Breij, Esther ...